ASP Isotopes (NASDAQ:ASPI) Chairman Paul Elliot Mann Sells 162,153 Shares

ASP Isotopes Inc. (NASDAQ:ASPI) Chairman Paul Elliot Mann sold 162,153 shares of the stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $5.75, for a total transaction of $932,379.75. Following the completion of the transaction, the chairman owned 7,759,538 shares of the company’s stock, valued at approximately $44,617,343.50. The trade was a 2.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Paul Elliot Mann also recently made the following trade(s):

• On Tuesday, November 25th, Paul Elliot Mann sold 50,000 shares of ASP Isotopes stock. The stock was sold at an average price of $5.77, for a total transaction of $288,500.00.
• On Monday, November 17th, Paul Elliot Mann sold 112,500 shares of ASP Isotopes stock. The stock was sold at an average price of $7.51, for a total transaction of $844,875.00.
• On Monday, September 8th, Paul Elliot Mann sold 81,076 shares of ASP Isotopes stock. The shares were sold at an average price of $8.53, for a total transaction of $691,578.28.
• On Tuesday, September 9th, Paul Elliot Mann sold 81,077 shares of ASP Isotopes stock. The shares were sold at an average price of $8.39, for a total transaction of $680,236.03.

ASP Isotopes Stock Up 2.7%

Shares of ASPI traded up $0.15 during mid-day trading on Wednesday, reaching $5.73. The company had a trading volume of 5,951,981 shares, compared to its average volume of 6,730,258. The company has a debt-to-equity ratio of 1.04, a quick ratio of 6.10 and a current ratio of 6.14. The company has a market capitalization of $635.11 million, a price-to-earnings ratio of -4.41 and a beta of 3.41. The firm has a 50-day moving average price of $8.85 and a 200 day moving average price of $8.78. ASP Isotopes Inc. has a 52 week low of $3.65 and a 52 week high of $14.49.

ASP Isotopes (NASDAQ:ASPI) last announced its quarterly earnings data on Wednesday, November 19th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.05). ASP Isotopes had a negative net margin of 1,259.12% and a negative return on equity of 190.44%. The company had revenue of $4.89 million for the quarter, compared to analysts’ expectations of $2.25 million. On average, sell-side analysts forecast that ASP Isotopes Inc. will post -0.24 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on ASPI shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of ASP Isotopes in a research note on Monday. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $11.00 target price on shares of ASP Isotopes in a report on Monday, November 24th. Finally, Loop Capital set a $15.00 price target on shares of ASP Isotopes in a report on Monday, October 27th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, ASP Isotopes presently has a consensus rating of “Hold” and an average target price of $13.00.

Institutional Investors Weigh In On ASP Isotopes

A number of large investors have recently added to or reduced their stakes in the stock. Exchange Traded Concepts LLC purchased a new position in shares of ASP Isotopes in the 2nd quarter worth $9,593,000. AlphaQuest LLC purchased a new stake in ASP Isotopes during the second quarter valued at $256,000. Rovida Advisors Inc. bought a new position in ASP Isotopes in the second quarter valued at about $16,148,000. Harbour Capital Advisors LLC purchased a new position in ASP Isotopes in the second quarter worth about $232,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in ASP Isotopes in the second quarter worth about $331,000. Institutional investors own 16.80% of the company’s stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.